The Integrated Forecasting and Analysis Tool   Login Now

Covidien

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Covidien are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Covidien, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Covidien - Divalproex Sodium Central Nervous System Anti-epileptics GABA agonist Filed   - Gatifloxacin Systemic Anti-infectives Anti-bacterials Quinolone Filed   - Radionuclide Therapy Various Diagnostic imaging Radiodiagnostic agent Research project

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Covidien   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 23,745 23,745        PE Ratio (diluted) - Normalised (x) 19.9 16.1        Valuing the Enterprise        Enterprise Value 26,516 26,516        Free Cash Flow (Pre-Dividends) 2,182 885        FCF Yield (%) 8.2% 3.3%    Forecast Financials   Income Statement      Total Revenues 9,535 9,647      Cost of Goods Sold (4,835) (5,161)      S,G & A (2,325) (2,081)      R&D (232) (262)      Other Income/ Expense - Net (248) (15)      EBIT - Normalised 1,895 2,128      Net Interest & Financial Items (166) (139)      Pre-tax Profits - Normalised 1,729 1,989      Exceptionals (5) (15)      Income Before Taxes 1,724 1,974      Tax (531) (504)      Tax Rate (%) 30.8% 25.5%      Discontinued Items (158) (315)      Net Income - Reported 1,035 1,155      Net Income - Normalised 1,196 1,481     Per Share Data      EPS - Diluted 2.08 2.32      EPS - Basic 2.08 2.32      EPS - Normalised (diluted) 2.41 2.98      EPS - Normalised (basic) 2.41 2.98      Avg. Shares Outstanding - Diluted 497.0 497.0      Avg. Shares Outstanding - Basic 497.0 497.0      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Covidien Launches Sandman Info(TM) and Sandman Auto(TM) CPAP Devices in the United States   (Covidien)   05-Jun-2008 Covidien Receives FDA Clearance to Market Single-Incision Laparoscopic Surgery (SILS(TM)) Kit   (Covidien)   20-May-2008 Covidien Introduces AbsorbaTack(TM) 5mm Hernia Fixation Device Featuring Absorbable Tacks in Europe   (Covidien)   13-May-2008 FDA Approves Covidien Contrast Delivery System with RFID   (Covidien)   07-May-2008 Covidien Introduces the VascuSeal(TM) Vascular Sealant System to the European Marketplace   (Covidien)   01-May-2008 EPIX Pharmaceuticals Announces Positive Results From Re-Read of Vasovist(R) Phase 3 Images   (EPIX Pharmaceuticals)   23-Apr-2008 Covidien Unveils the Next Generation in Advanced Surgery   (Covidien)   10-Apr-2008 Covidien Launches Endo Clip(TM) III 5mm Clip Applier   (Covidien)   01-Apr-2008 Covidien Launches Three Access Products in Europe for Advanced Minimally Invasive Procedures   (Covidien)   31-Mar-2008 Covidien Introduces Three Access Products for Advanced Minimally Invasive Procedures   (Covidien)   04-Mar-2008 Covidien Announces Tentative FDA Approval for Its Generic Myocardial Perfusion Imaging Kit   (Covidien)   27-Feb-2008 Covidien Introduces Sandman Intro(TM) CPAP Device   (Covidien)   11-Feb-2008 EPIX Pharmaceuticals Reaches Agreement with FDA on Protocol, Initiates Re-Read of Vasovist(TM) Phase 3 Images   (EPIX Pharmaceuticals)   31-Jan-2008 Covidien Introduces AbsorbaTack(TM) 5mm Hernia Fixation Device Featuring Absorbable Tacks   (Covidien)   17-Jan-2008 Covidien Introduces PleuraSeal(TM) Lung Sealant System to European Marketplace   (Covidien)   09-Nov-2007 Ambrilia Reports Positive Results From Phase 2 Study of its Prolonged Release Formulation of Octreotide   (Ambrilia Biopharma)   29-Aug-2007 Ambrilia Completes Patient Recruitment for the Phase 3 Pivotal Clinical Trial of its Prolonged Release Formulation of Octreotide   (Ambrilia Biopharma)   28-Aug-2007 Covidien's MRidium Infusion Pump Delivers Industry-Leading Functionality for Magnetic Resonance Imaging   (Covidien)   16-Aug-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Covidien Acetaminophen & codeine phosphate acetaminophen & codeine   Albunex albumin   Anafranil clomipramine   Anatrast barium sulfate   Anexsia acetaminophen & hydrocodone   Atenolol atenolol   Baricon barium sulfate   Baro-Cat barium sulfate   Baros sodium bicarbonate & tartaric acid   Barosperse barium sulfate   Bear-E-Yum GI barium sulfate   Butalbital, Acetaminophen & Caffeine butalbital, acetaminophen & caffeine   CEA-Scan arcitumomab   CheeTah barium sulfate   Conray iothalamate meglumine   Cysto-Conray II iothalamate meglumine   Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate & Amp Sulfate dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate & amphetamine sulfate   Dextroamphetamine Sulfate dextroamphetamine   Digital HD barium sulfate   Divalproex Sodium divalproex sodium   Enhancer barium sulfate   Entrobar barium sulfate   Entrocel methylcellulose   EntroEase barium sulfate   Epi-C barium sulfate   Flo-Coat barium sulfate   Fluoxetine fluoxetine   Gallium Citrate gallium Ga-67 citrate   GastroMARK ferumoxsil   Gatifloxacin gatifloxacin   HD 200 PLUS barium sulfate   HD 85 barium sulfate   Hexabrix ioxaglate meglumine & ioxaglate sodium   Hydrocet acetaminophen & hydrocodone   Hydrocodone Bitartrate & Acetaminophen acetaminophen & hydrocodone   Hydromorphone Hydrochloride hydromorphone   Imager barium sulfate   Indium Chloride indium In-111 chloride   InterSource 103 palladium Pd-103   InterSource 125 iodine I-125   Intropaste barium sulfate   Liqui-Coat HD barium sulfate   Lorcet-HD acetaminophen & hydrocodone   Magnacet acetaminophen & oxycodone   MD-76R diatrizoate meglumine & diatrizoate sodium   MD-Gastroview diatrizoate meglumine & diatrizoate sodium   Medebar Plus barium sulfate   Medescan barium sulfate   Meperidine Hydrochloride meperidine   Metformin Hydrochloride metformin   Methadone Hydrochloride methadone   Methadose methadone   Methylin methylphenidate   Methylphenidate hydrochloride methylphenidate   Morphine sulfate morphine sulfate   Myoview technetium Tc-99m tetrofosmin   Naltrexone Hydrochloride naltrexone   NeutroSpec technetium Tc-99m fanolesomab   OctreoScan indium In-111 pentetreotide   OptiMARK gadoversetamide   Optiray ioversol   Optison octafluoropropane   Osteoscan technetium Tc-99m etidronate   Oxycet acetaminophen & oxycodone   Oxycodone & acetaminophen acetaminophen & oxycodone   Oxycodone Hydrochloride oxycodone   Pamelor nortriptyline   Pemoline pemoline   Phendimetrazine Tartrate phendimetrazine   Phosphocol chromic phosphate P-32   Prepcat barium sulfate   Promethazine Hydrochloride promethazine   Propoxyphene Napsylate & Acetaminophen propoxyphene napsylate & acetaminophen   ProstaSeed iodine I-125   Radionuclide Therapy -   Restoril temazepam   Ribavirin ribavirin   Scan C barium sulfate   Selenomethionine SE 75 Selenomethionine SE-75   Sodium Chromate sodium chromate Cr-51   Sodium Iodide (I-123) sodium iodide I-123   Sodium Iodide (I-131) sodium iodide I-131   Sodium Phosphate sodium phosphate P-32   Sonazoid perflubutane   Technescan DTPA technetium Tc-99m pentetate   TechneScan Gluceptate technetium Tc-99m gluceptate   TechneScan HDP technetium Tc-99m oxidronate   Technescan MAA technetium Tc-99 albumin   TechneScan MAG3 technetium Tc-99m mertiatide   TechneScan PYP technetium Tc-99m pyrophosphate   TechneScan Q12 technetium Tc-99m furifosmin   Technetium Tc 99m Sestamibi technetium Tc-99m sestamibi   Technetium Tc-99m Medronate technetium Tc-99m medronate   Thallous Chloride thallous Tl-201 chloride   Tofranil imipramine   Tofranil-PM imipramine pamoate   Tomocat barium sulfate   Tonopaque barium sulfate   Tramadol Hydrochloride tramadol   Tridrate magnesium citrate   Tussicaps chlorpheniramine polistirex & hydrocodone polistirex   Tussizone-12 RF carbetapentane & chlorpheniramine   UltraTag technetium Tc-99m   Vasovist gadofosveset   Warfarin Sodium warfarin sodium   Xenon Xenon XE-133

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 14:01:39 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd